Drug Trial Radar · NCT06918925
First-In-Human Study to Evaluate Single and Multiple Ascending Doses of JUV-161 in Healthy Adult Volunteers
Last checked: Nov 20, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
72
Actual
Start
May 14, 2025
Primary completion
May 30, 2026
Study completion Sep 30, 2026
Sponsor
- Lead sponsor
- Juvena TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Apr 9, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The present First-In-Human (FIH) study (JUV-161-101) aims to assess the safety, tolerability, and pharmacokinetics (PK) of single and multiple subcutaneous (SC) doses of JUV-161 in healthy volunteers. The study design is well-established for FIH studies and appropriate to assess the preliminary safety and tolerability of new drug candidates. Data from this study will support conduct studies in patients with DM1 as well as supporting studies in other degenerative myopathies and other disorders for which preclinical efficacy data have been obtained.JUV-161 has not been previously been administered to human subjects.
Conditions
- Healthy Volunteer
Interventions
JUV-161, PlaceboDrug
Single-Ascending, Placebo-Controlled
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment-emergent adverse eventsTime frame: From enrollment through to safety follow-up Visit on Day 60
- Number of participants with treatment-emergent potentially clinically-significant safety abnormalities in safety laboratory parametersTime frame: From enrollment through to safety follow-up Visit on Day 60
- Number of participants who have changes from baseline in electrocardiogram values in QTcF intervalsTime frame: From enrollment through the safety follow-up visit on Day 60
- Number of participants who have changes from baseline in heart rate ( beats per minute)Time frame: From enrollment through the safety follow-up visit on Day 60
- Number of participants who have a change from baseline in systolic and diastolic blood pressure (mmHg)Time frame: From enrollment through the safety follow-up visit on Day 60
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Nucleus Network Pty Ltd
Melbourne, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.